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Abstract 
Background: Pregnant women are a high‑risk group for Plasmodium falciparum infections, which may result in 
maternal anaemia and low birth weight newborns, among other adverse birth outcomes. Intermittent preventive 
treatment with sulfadoxine–pyrimethamine during pregnancy (IPTp‑SP) is widely implemented to prevent these 
negative effects of malaria. However, resistance against SP by P. falciparum may decrease efficacy of IPTp‑SP. Combi‑
nations of point mutations in the dhps (codons A437, K540) and dhfr genes (codons N51, C59, S108) of P. falciparum 
are associated with SP resistance. In this study the prevalence of SP resistance mutations was determined among P. 
falciparum found in pregnant women and the general population (GP) from Nanoro, Burkina Faso and the association 
of IPTp‑SP dosing and other variables with mutations was studied.
Methods: Blood spots on filter papers were collected from pregnant women at their first antenatal care visit (ANC 
booking) and at delivery, from an ongoing trial and from the GP in a cross‑sectional survey. The dhps and dhfr genes 
were amplified by nested PCR and products were sequenced to identify mutations conferring resistance (ANC book‑
ing, n = 400; delivery, n = 223; GP, n = 400). Prevalence was estimated with generalized estimating equations and for 
multivariate analyses mixed effects logistic regression was used.
Results: The prevalence of the triple dhfr mutation was high, and significantly higher in the GP and at delivery than 
at ANC booking, but it did not affect birth weight. Furthermore, quintuple mutations (triple dhfr and double dhps 
mutations) were found for the first time in Burkina Faso. IPTp‑SP did not significantly affect the occurrence of any of 
the mutations, but high transmission season was associated with increased mutation prevalence in delivery samples. 
It is unclear why the prevalence of mutations was higher in the GP than in pregnant women at ANC booking.
Conclusion: The high number of mutants and the presence of quintuple mutants in Burkina Faso confirm concerns 
about the efficacy of IPTp‑SP in the near future. Other drug combinations to tackle malaria in pregnancy should, 
therefore, be explored. An increase in mutation prevalence due to IPTp‑SP dosing could not be confirmed.
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Background
Malaria remains an important cause of morbidity and 
mortality worldwide, in particular in sub-Saharan Africa 
(SSA) [1]. Certain populations, in particular children 
under five years of age and pregnant women, are more at 
risk of developing clinical malaria. Young children gener-
ally experience multiple episodes of clinical (sometimes 
severe) malaria before acquiring partial immunity against 
this disease [2, 3]. In areas where malaria transmission is 
stable, women have acquired partial immunity, but they 
remain vulnerable to malaria when they get pregnant 
due to specific surface antigens on Plasmodium falcipa-
rum-infected erythrocytes that are almost exclusively 
presented by the malaria parasite during pregnancy [4]. 
This leaves in particular primigravidae, who are exposed 
to these antigens for the first time, more vulnerable to 
malaria infection. Women who are more frequently 
exposed to these pregnancy-associated malaria antigens, 
like multigravidae, can acquire a certain degree of immu-
nity and are therefore less severely affected by malaria 
in pregnancy [5–8]. Malaria in pregnancy may result in 
maternal anaemia, low birth weight, pre-term birth, still 
birth, and infant and maternal deaths [9, 10]. Most SSA 
countries have implemented preventive anti-malarial 
treatment schedules to protect the high-risk groups, such 
as intermittent preventive treatment in infants (IPTi) or 
pregnant women (IPTp). In IPTp, pregnant women in 
their second and third trimester of pregnancy living in 
moderate to high malaria transmission areas are offered 
sulfadoxine–pyrimethamine (SP) at each antenatal care 
(ANC) visit, irrespective of clinical malaria symptoms or 
diagnostic test results [11]. SP is a suitable drug for this 
preventive regimen because of its excellent safety profile 
during pregnancy and its prophylactic efficacy [12, 13]. 
However, although IPTp-SP has greatly reduced mor-
bidity in pregnant women and their offspring, there are 
growing concerns about its waning efficacy due to an 
increase in parasite resistance against SP [14, 15]. In par-
ticular, in certain parts of East Africa resistance against 
SP is extremely high necessitating alternative preven-
tive strategies [16, 17]. In West Africa resistance against 
SP is rising, but IPTp-SP is still considered efficacious 
[18]. Nevertheless, monitoring SP resistance is of utmost 
importance to ensure timely changes in policy. Emer-
gence of SP resistance can be monitored by determining 
the prevalence of mutations in two genes of P. falcipa-
rum, dihydropteroate synthase (dhps) and dihydrofolate 
reductase (dhfr), associated with resistance against sulf-
adoxine and pyrimethamine, respectively. Accumulation 
of single point mutations in these genes leads to increas-
ing SP resistance, particularly the combined triple dhfr 
(N51, C59, S108) and double dhps (A437, K540) muta-
tions (quintuple mutant) [19].
In Burkina Faso, SP was used as first-line malaria treat-
ment until 2005 but has since been used only for IPTp-SP 
and IPTi [20]. Mutations in the dhps and dhfr gene are 
nevertheless still increasing (around 10–30% increase 
from 2009 to 2012) [15]. This may be due to the contin-
ued use of SP in IPTi and IPTp programmes that are still 
causing selection of SP-resistant parasites. In the present 
study, carried out in central Western Burkina Faso, the 
prevalence of the main SP resistance related mutations 
(dhps S436, A437, K540 and dhfr N51, C59, S108 codons) 
was determined in pregnant women at ANC booking, at 
delivery and in the general population (GP) [15, 21–23]. 
It was hypothesized that the prevalence of SP resistance 
mutations would increase over pregnancy due to expo-
sure to IPTp-SP, thus reaching the highest prevalence at 
delivery. The comparison with the GP was made to inves-
tigate whether pregnant women unexposed to IPTp-SP 
(at ANC booking) show comparable mutation preva-
lence to the GP. Furthermore, this study aimed to iden-
tify factors other than IPTp-SP that are associated with 
increased risk of finding mutant parasites.
Methods
COSMIC: study population and procedures
This study was done in the framework of a cluster-ran-
domized intervention trial (Community-based sched-
uled screening and treatment of malaria in pregnancy 
for improved maternal and infant health: a cluster-
randomized trial, or COSMIC, registration numbers 
ISRCTN372259296 Current Controlled Trials and 
NCT01941564 clinicaltrials.gov). The study was situated 
in the Nanoro health centre catchment area, which is a 
rural area located 85 km northwest of Ouagadougou. The 
area is highly endemic for malaria with the peak trans-
mission season occurring towards the end of the rainy 
season, which lasts from June until October. The COS-
MIC trial has been described elsewhere [24]. Briefly, 
the intervention trial investigated the effect of malaria 
screening and treatment of pregnant women by commu-
nity health workers at village level on placental malaria 
and low birth weight. The study was implemented in 30 
villages, 15 control and 15 intervention villages. Women 
from both control and intervention villages were enrolled 
in the study at their first ANC visit at which they received 
standard care, including IPTp-SP according to national 
guidelines. Women were subsequently followed up 
until delivery. At each ANC visit and at delivery a blood 
slide was collected and blood was spotted on Whatman 
3MM filter paper or 1MM filter paper (spots of at least 
12-mm diameter), depending on availability. In inter-
vention villages, pregnant women also received monthly 
malaria screening at village level with rapid diagnos-
tic test (RDT, SD Bioline Ag-Pf). In case of a positive 
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RDT artemisinin-based combination therapy was given 
(artemether–lumefantrine). At delivery, the birth weight 
of the newborn was collected for all participants. ANC 
booking and delivery samples collected from May 2014 
until September 2015 were tested for P. falciparum by 
real-time PCR. All P. falciparum-positive delivery sam-
ples and 400 randomly selected positive ANC booking 
samples were included in the analyses of SP resistance 
markers.
Cross‑sectional survey: study population and procedures
Samples from the GP were collected from March until 
May 2015 in the Nanoro health centre catchment area in 
the same villages as the COSMIC study (n =  30). Field 
workers and nurses were trained for 1 week on malaria, 
its clinical symptoms, RDT diagnosis, blood spot col-
lection, treatment of malaria, and in obtaining informed 
consent. In each household two members were ran-
domly selected for the survey. In each village 20 house-
holds were randomly selected from the database of the 
Health and Demographic Surveillance System. For 205 
selected households, the residents were not present at 
the time of visit and these were therefore replaced by 
205 other randomly selected households. Participants 
had to be ≥6 months of age. Pregnant women or partici-
pants that reported SP use in the past 2 weeks were not 
enrolled. After informed consent was obtained, medi-
cal history and clinical symptoms or signs of malaria 
were recorded by the field workers or nurses. The nurses 
subsequently performed a RDT (SD Bioline Ag-Pf) and 
collected blood spots of at least 12-mm diameter on 
Whatman 3MM filter paper. RDT-positive participants 
were treated according to national guidelines. All filter 
paper samples were tested for P. falciparum by real-time 
PCR, 400 positive samples were randomly selected to 
study the SP resistance markers.
Filter paper processing and DNA extraction
Blood spots on filter paper were air dried, put in sealable 
bags with silica and transported on the same day from 
the field to the laboratory (Unité de Recherche Clinique 
de Nanoro-URCN). Filter paper samples were stored at 
ambient temperature until shipment to the laboratory in 
The Netherlands. From each filter paper, one blood spot 
was punched out using Acu-punch skin biopsy punch-
ers  (Acuderm® Inc, USA) and transferred into a 5-mL 
polystyrene tube. Subsequently 2  ml of EasyMAG lysis 
buffer (bioMérieux, Marcy-l’Étoile, France) was added 
to the tubes after which they were put on a roller bank 
for 30  min for thorough lysis. After lysis, the fluid was 
transferred to EasyMAG vessels and magnetic bead sil-
ica were added to each well according to manufacturer’s 
instructions. DNA was extracted with DBS 1.0 protocol 
in the NucliSENS EasyMAG. Positive controls (blood 
spots from diluted P. falciparum 3D7 or FCR3 in  vitro 
culture) and negative controls (blood spots of uninfected 
erythrocytes obtained from the Dutch Blood Bank) were 
included. Samples of extracted DNA were stored at 
−20 °C until further use.
Real‑time PCR
Plasmodium falciparum DNA was detected by real-time 
PCR, as described previously, with minor adjustments 
in primer concentrations and probe sequence [25–27]. 
Per reaction, 2.5  µl of DNA, 5  mM  MgCl2, 2.5  µl of 
10× PCR Buffer, 0.125 µl of HotStarTaq DNA Polymer-
ase, 0.25 mM of each dNTP, 0.4 µM of each primer and 
0.1 µM of FAM-labelled probe (′5-aacaattggagggcaagg-3′) 
were used. All PCR mix reagents were ordered from 
Qiagen (Hilden, Germany) and all primers from Biole-
gio (Nijmegen, The Netherlands). In each plate a dilu-
tion series of P. falciparum FCR3 culture was included 
(tenfold dilution steps with highest value  104 parasites/
µl and a lowest value of 1 parasites/µl) as well as positive 
and negative DNA extraction controls and Milli-Q water. 
The dilution series were used to make an estimation of 
the parasitaemia. Reactions were run on BioRad CFX 
real-time PCR machine with the following settings: initial 
denaturation 95 °C for 10 min, 40 cycles of 95 °C for 60 s 
and 60 °C for 20 s. Results were analysed using Bio-Rad 
CFX manager software (version 3.1).
Nested PCR and sequencing
Nested PCR was used to amplify the dhfr and dhps gene 
regions covering the codons of interest. Nest 1 primers 
were described in Duraisingh et al. [28]. Nest 2 primers 
were located just inwards of nest 1 primers (Table  1). 
All primers were ordered from Biolegio (Nijmegen, 
The Netherlands). For nest 1 dhfr PCR, 2.5  µl of DNA, 
Table 1 Primer sequences used for nested PCR and sequenc-
ing of Plasmodium falciparum dhfr and dhps genes
Primer name Sequences
Nest 1 forward dhfr 5′‑TTTATGATGGAACAAGTCTGC‑3′
Nest 1 reverse dhfr 5′‑AGTATATACATCGCTAACAGA‑3′
Nest 2 forward dhfr 5′‑TCTGCGACGTTTTCGATATTT‑3′
Nest 2 reverse dhfr 5′‑CTCATTTTCATTTATTTCTGGA‑3′
Nest 1 forward dhps 5′‑AACCTAAACGTGCTGTTCAA‑3′
Nest 1 reverse dhps 5′‑AATTGTGTGATTTGTCCACAA‑3′
Nest 2 forward dhps 5′‑CCTAAACGTGCTGTTCAAAGAA‑3′
Nest 2 reverse dhps 5′‑TTGTTCATCATGTAATTTTTGTTGTG‑3′
Nest 2 reverse2 dhps 5′‑CAATACTTATAATTGGTTTCGCATCA‑3′ 
(sequencing only)
Nest 2 reverse 540 dhps 5′‑TTCGCAAATCCTAATCCAATATC‑3′ 
(sequencing only)
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1 mM  MgCl2, 2.5 µl of 10× PCR Buffer, 0.125 µl of Hot-
StarTaq DNA Polymerase, 0.25  mM of each dNTP, 
and 0.4  µM of each primer were used per reaction. For 
nest 1 dhps the same reagents were used except that 
2  mM of  MgCl2 was used instead of 1  mM. For nest 2, 
both PCRs used 0.5 µl of nest 1 product, 2 mM  MgCl2, 
2.5  µl of 10× PCR Buffer, 0.125  µl of HotStarTaq DNA 
Polymerase, 0.25 mM of each dNTP and 0.4 µM of each 
primer. All PCR mix ingredients were ordered from Qia-
gen (Hilden, Germany). Nest 1 PCR settings were: initial 
denaturation at 94 °C for 10 min, 28 cycles of 94 °C 1 min, 
58 °C 1 min, 74 °C 1 min. Nest 2 PCR settings were: ini-
tial denaturation at 94  °C for 10 min, 40 cycles of 94  °C 
1 min, 58 °C 1 min, 74 °C 1 min. Positive (P. falciparum 
D10 genomic DNA, MRA-201G, MR4,  ATCC® Manas-
sas Virginia, USA) and negative controls (uninfected 
erythrocytes) were included in each PCR. Products were 
run on a 1% agarose gel. Clear bands of the correct size 
were sent for sequencing with the corresponding nest 2 
primers (Macrogen, Amsterdam, The Netherlands). For 
dhps, two additional reverse primers were used for a 
total of four sequencing reactions (Table 1). In this way 
a homopolymer region in the middle of the dhps PCR 
product, that caused polymerase slippage, was circum-
vented. Results were analysed with Geneious 8.1.8 using 
a P. falciparum 3D7 reference genome. Base pair calling 
was manually confirmed in both sequencing directions 
for each sample (or the two reverse directions for dhps 
K540). Heterozygote results had to be confirmed in both 
sequencing directions to be qualified as a mixed infec-
tion. Mixed infections were considered mutants in the 
initial analyses.
Statistical analysis
Data were analysed using Stata 14.1. Descriptive statistics 
were used to identify the characteristics of the three study 
populations (ANC booking, delivery, GP). Clustering 
was present at village level and also because of repeated 
measurements (some women were included in both the 
ANC samples and delivery samples). In each of the three 
study populations, mutation prevalence with 95% confi-
dence intervals was estimated by generalized estimating 
equations with village as panel variable in order to obtain 
a population-averaged effect. However, to enable multi-
ple levels in some of the univariate and multivariate mod-
els explaining the mutation prevalence in the data sets, 
for example, repeated measurements in pregnant women 
who are clustered in villages, mixed effects logistic 
regressions were used for all explanatory models. Type of 
visit (ANC versus delivery and ANC versus GP), IPTp-SP 
doses or IPTp-SP dose in past 30 days, and other varia-
bles, such as age, parasitaemia, artemether–lumefantrine 
treatment, gravidity, and season were used as fixed effects 
in univariate mixed effects logistic regressions for each 
mutation of interest. The high transmission season was 
defined as the period between June and November. All 
variables of the univariate analyses were also included in 
the multivariate model, except parasitaemia because this 
was considered an intermediate variable for the effect of 
IPTp-SP doses on the outcome. In the multivariate model 
for pregnant women, an interaction effect was added for 
season versus visit, denoted seasonXvisit, and for gravid-
ity versus visit, denoted gravidityXvisit. For both preg-
nant women and the ANC/GP model, an interaction 
effect for age and visit was included, denoted ageXvisit. 
Age was centred at 25 years (median of pregnant women) 
and reported per 10-year increase. For analyses of each of 
the three study populations and for ANC and GP samples 
combined, only village was included as random inter-
cept. For analyses of the ANC and delivery combined 
sample set, participant identifier was nested within vil-
lage as random intercepts. Household was not included 
as random variable because no information was available 
about overlapping households between pregnant women 
and the GP. After initial analyses in which mixed infec-
tions were considered mutants, the same analyses were 
conducted for pure mutants versus mixed and wild type 
infections combined.
Lastly, univariate and multivariate analyses were per-
formed on the association between the triple dhfr muta-
tion and low birth weight (<2500 g) in delivery samples, 
using village as a random effect and covariates IPTp-SP 
dosing, season, gravidity, age and artemether-lumefan-
trine exposure as fixed effects. The confidence intervals 
and p values of all conducted analyses are shown, unad-
justed for multiple comparisons.
Results
COSMIC: mutation prevalence and predicting factors
About half of the samples collected at ANC booking 
(591/1175, 50.3%) were tested positive for P. falcipa-
rum by real-time PCR while this was 17.9% (223/1248) 
at delivery. A random selection of 400 P. falciparum-
positive ANC samples and all 223 positive delivery sam-
ples were included for mutation analyses by sequencing 
(Fig. 1). Characteristics of the participants for each study 
population are presented in Table  2. Almost all women 
received at least one dose of IPTp-SP. 57.4% received the 
former recommended minimum of two doses of IPTp-SP 
and 15.3% received four or more doses of IPTp-SP. Para-
site density was generally lower at delivery than at ANC, 
with a median of 6 and 30 parasites/µl, respectively.
Sequence results for the three codons associated with 
SP resistance in the dhps gene (S436, A437, K540) could 
be obtained from 359 (89.8%) ANC samples and 175 
(78.5%) delivery samples. For the three dhfr codons (N51, 
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C59, S108) results were available for 380 (95.0%) ANC 
and 186 (83.4%) delivery samples. High proportions of 
mutant parasites were found for all codons and the tri-
ple dhfr mutation in both study populations, but not for 
dhps K540 (Table 3 and Additional file 1: Table S1). The 
K540 mutation was detected in two delivery samples. 
As the dhps A437 and the triple dhfr mutation were also 
detected in these samples, parasites in these samples 
can thus be considered quintuple mutants. In univariate 
mixed effects logistic regression analyses delivery sam-
ples showed significantly higher prevalence of mutations 
compared with ANC samples for dhps A437 (p = 0.037), 
dhfr C59 (p  =  0.013), dhfr S108 (p  =  0.016) and triple 
dhfr mutations (p =  0.029) and a trend for higher dhfr 
N51 (p = 0.069) mutations (Additional file 2: Table S2). 
Univariate analyses also revealed a significant positive 
association between gravidity and all dhfr mutations and 
between rainy season and all dhfr mutations for delivery 
samples (p  <  0.05 and p  <  0.01, respectively). Increased 
age was associated with a higher risk of dhfr N51 
(p = 0.004) and triple dhfr mutations (p = 0.005) in ANC 
samples, while treatment with artemether–lumefantrine 
Fig. 1 Flowchart of the longitudinal survey of SP resistance mutations in pregnant women
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was associated with a higher risk of the same mutations 
in delivery samples (p  =  0.001 and p  =  0.002, respec-
tively). No significant associations were seen for parasi-
taemia or IPTp-SP doses (Additional file 2: Table S2).
Univariate analyses for the outcome of low birth weight 
at delivery did not show an association with the triple 
dhfr mutation, but IPTp-SP doses, age and gravidity were 
all protective of low birth weight (p =  0.003, p =  0.046 
and p = 0.004, respectively) (Additional file 3: Table S3).
In multivariate analyses (Table  4) for ANC and deliv-
ery samples, there was no significant association between 
number of IPTp-SP doses and prevalence of SP resist-
ance mutations (p > 0.05). The inclusion of SP exposure 
in the past 30 days in the model, instead of the number 
of SP doses, resulted in larger odds ratios (OR) but the 
associations were still not significant (Additional file  4: 
Table  S4). The interaction term between age and visit 
was not significant, but a significantly lower prevalence 
of dhfr N51 (p = 0.010) and triple dhfr (p = 0.010) muta-
tions was seen for older age at ANC booking. This was 
seen to a lesser extent (p  =  0.075 and p  =  0.051), in 
delivery samples. Higher gravidity resulted in increased 
prevalence of mutations in delivery samples (significant 
for dhfr N51, p = 0.042, and triple dhfr, p = 0.024, muta-
tions). Delivery samples showed increased prevalence of 
dhfr mutations in high transmission season compared 
Table 2 Characteristics of study participants in the longitudinal and cross-sectional survey
Characteristics Longitudinal survey Cross‑sectional survey
ANC booking (n = 400) Delivery (n = 223) GP (n = 400)
Age in years, median (IQR) 24 (20–28.5) 25 (19–30) 10 (6–25)
Female, % 100 100 52
Gravidity
 Primigravidae, % 25.8 28.3 NA
 Secundigravidae, % 20.0 12.6 NA
 Multigravidae, % 54.3 59.2 NA
Number of IPTp‑SP doses, %
 0 NA 0.5 NA
 1 NA 15.3 NA
 2 NA 57.4 NA
 3 NA 11.7 NA
 4+ NA 15.3 NA
Temperature  °C, mean (IQR) 36.7 (36.4–37.0) 36.8 (36.5–37.1) 36.9 (36.6–37.0)
Fever, temperature >37.5 °C,  % 1.5 10.0 1.5
Parasitaemia p/µl, median (IQR) 30 (7–147) 6 (1–102) 22 (4–141)
Parasitaemia sub‑groups p/µl, %
 0–10 32.8 54.7 39.3
 10–100 37.8 20.2 31.5
 100–1000 25.5 15.3 23.8
 1000–10,000 4 8.1 5
 >10,000 0 1.8 0.5
Birth weight in grams, mean (SD) NA 2950 (520) NA
Low birth weight (<2500 g), % NA 16.7 NA
Table 3 Prevalence of Plasmodium falciparum double dhps, triple dhfr and quintuple mutations in ANC, delivery and GP 
samples
ANC booking Delivery GP
% mutant (95% CI) N % mutant (95% CI) N % mutant (95% CI) N
Double dhps mutation 0 359 1.1 (0.3–4.4) 175 1.1 (0.4–2.8) 352
Triple dhfr mutation 61.1 (56.2–65.2) 380 70.5 (63.9–76.5) 182 73.9 (67.9–78.9) 355
Quintuple mutation 0 353 1.2 (0.3–4.6) 168 0.9 (0.3–2.6) 336
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with low transmission season (p  =  0.007, p  =  0.015, 
p =  0.016, p =  0.002 for dhfr N51, dhfr C59, dhfr S108 
and triple dhfr, respectively). For ANC samples there was 
no such seasonal difference. For the dhps gene there were 
no significant variables in multivariate analyses except for 
decreased prevalence of dhps A437 mutations (p = 0.047) 
with increasing artemether–lumefantrine doses.
Multivariate analysis for the effect of the triple dhfr 
mutation on the outcome of low birth weight was con-
ducted for delivery samples including IPTp-SP doses, gra-
vidity, age, season and artemether–lumefantrine therapy. 
IPTp-SP and gravidity were both protective against low 
birth weight (p = 0.008 and p = 0.010, respectively), but 
none of the other variables was significantly associated 
with low birth weight (including the triple dhfr mutation) 
(Additional file 5: Table S5).
Cross‑sectional survey: mutation prevalence 
and predicting factors
Out of 1200 GP participants, 45.3% (544) were tested 
positive for P. falciparum by real-time PCR. 400 posi-
tive samples were randomly selected for mutation analy-
ses (Fig.  2). Characteristics of included participants are 
shown in Table  2. The median age of participants was 
10 years and 52% were female. The median parasite den-
sity was 22 p/µl.
Sequence results could be obtained from 352 (88.0%) 
dhps samples and 355 (88.8%) dhfr samples. There were 
six samples with good quality sequence results for only 
the dhps K540 codon and one sample for only the dhps 
S436, A437 codons. All tested codons showed high pro-
portions of mutants, except for dhps K540 which was 
found in only four of the 358 samples (Table  3). Three 
of these were quintuple mutants, the fourth had missing 
data for the dhfr sequence. The proportions of mutants 
in GP samples were higher compared with ANC samples, 
but were similar to delivery samples. In univariate analy-
sis GP samples showed significantly higher prevalences 
of dhfr N51, C59, S108, triple dhfr mutations, and dhps 
S436 mutations (all p < 0.001) compared with ANC sam-
ples. Delivery and GP samples were not significantly dif-
ferent (Additional file 2: Table S2).
In multivariate analyses (Table 5) for GP and ANC sam-
ples, older age was again associated with decreased prev-
alence of dhfr N51 (p = 0.004) and triple dhfr (p = 0.005) 
mutations for pregnant women at ANC booking, but 
there was no association of age with mutation preva-
lence in GP samples. For participants of the same age, 
GP samples showed significantly higher prevalence of 
all dhfr (p < 0.01) and dhps S436 (p = 0.014) mutations 
than ANC samples. However, in a sensitivity analysis in 
which age was restricted to 15–45 years in the GP group 
(range in pregnant women), GP showed a similar trend in 
age as ANC samples. GP still showed significantly higher 
dhfr N51 (p = 0.006) and triple dhfr mutation prevalence 
(p =  0.025) (Additional file 6: Table S6). Season was no 
significant predictor for any of the mutations.
Mutant versus mixed and wild type infections in ANC, 
delivery and GP samples
Stratifying the sequence results in mutant, mixed or 
wild type codons revealed that the difference in muta-
tion prevalence between ANC and delivery samples was 
mainly related to a difference in pure mutants, while the 
difference between ANC and GP samples was mainly 
related to a difference in mixed infections (Fig.  3). In 
univariate analyses for pure mutants versus mixed and 
wild type infections, delivery samples had significantly 
increased prevalence of all mutations compared with 
both ANC and GP samples (all dhfr mutations, p ≤ 0.001; 
triple dhfr mutation, p  ≤  0.001; dhps S436 mutation, 
p = 0.014 for ANC/delivery and p ≤ 0.001 for GP/deliv-
ery; and dhps A437 mutation, p  ≤  0.001). In contrast, 
GP and ANC samples showed comparable prevalence 
of resistance mutations (Additional file  7: Table S7). In 
multivariate analyses for pregnant women, high trans-
mission season resulted once again in increased dhfr 
mutation prevalence in delivery samples. Also higher 
gravidity remained associated with increased preva-
lence of dhfr N51 and triple dhfr mutations in delivery 
samples. The trend of a negative association between 
age and mutation prevalence in ANC and delivery sam-
ples remained, but this was only significant for the tri-
ple dhfr mutation in delivery samples (Additional file  8: 
Table S8). In the ANC/GP model none of the variables 
was significant, except for an association between older 
age and increased prevalence of mutations in codons dhfr 
N51, triple dhfr and dhps A437 (p = 0.046, p = 0.014 and 
p = 0.010, respectively) in GP samples (Additional file 9: 
Table S9).
Discussion
Overall the prevalence of SP resistance related muta-
tions was high among Burkinabe pregnant women and 
the non-pregnant population for all three dhfr codons 
studied (N51 ≥ 63.9%, C59 ≥ 71.6%, S108 ≥ 74.2%, tri-
ple dhfr ≥ 61.1%) and for two dhps codons (S436 ≥ 70.9% 
and A437 ≥ 79.4%). However, both delivery and GP sam-
ples showed significantly higher prevalence of dhfr and 
either S436 or A437 dhps mutations than ANC samples. 
In 2010 in the same region, the prevalence of SP resist-
ance mutations was considerably lower, especially for 
dhps codon A437 (34.2%), dhfr codon N51 (12.2%) and 
the dhfr triple mutation (11.4%) [23]. This suggests a 
substantial increase in mutation prevalence in a 5-year 
period. However, the previous study used a different 
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mutation analysis method, restriction fragment length 
polymorphism, which could also explain the differences. 
Recent studies in other regions of Burkina Faso reported 
prevalences of mutant parasites that were more similar 
to those observed here. In 2010–2011, among pregnant 
women at ANC booking, the prevalence of mutations 
in dhfr N51, C59, S108 codons (49.1, 50.4 and 57.8%, 
respectively) was lower but the prevalence of dhps S436 
and A437 mutations (81.2 and 75.2%, respectively) was 
similar to the currently presented results [22]. Between 
2009 and 2011 Geiger et  al. [15] showed an upward 
trend for prevalence of dhfr and dhps mutations in sam-
ples from the general population reaching comparable 
or higher levels to the prevalences reported here (from 
graph: S436 ± 88% A437 ± 80%, N51 ± 80%, C59 ± 90%, 
S108 ± 90%).
Another important finding was the presence of dhps 
K540 mutations in six samples, of which five were 
Fig. 2 Flowchart of the cross‑sectional survey of SP resistance mutations in the general population
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considered quintuple mutants. This is the first time quin-
tuple mutants are found in Burkina Faso. In 2002, the 
dhps K540 mutation was found in one study in Burkina 
Faso, but these were not quintuple mutants [29]. Despite 
the importance of this finding, for the current situation in 
which triple dhfr mutations are common but the quintu-
ple mutation is rare, IPTp-SP is still expected to be effica-
cious [18]. This is also substantiated by the finding that 
the triple dhfr mutation was not associated with low birth 
weight, while an increasing number of IPTp-SP doses did 
protect malaria infected women at delivery from giving 
birth to low birth weight babies.
Although the prevalence of mutations (codons dhps 
A437 and dhfr C59, S108 and the triple dhfr mutation) 
was higher at delivery than at ANC booking, there was 
no evidence of a significant association between IPTp-
SP doses and selection of resistant parasites. Because all 
but one woman had received at least one dose of IPTp-SP 
at delivery, a binary variable of IPTp-SP exposure could 
not be included in the regression model. SP exposure in 
the past 30  days was also included as a binary variable, 
to account for time between SP exposure and sampling, 
but the results were still not significant. Previous studies 
on the selection of SP resistance mutations by IPTp-SP 
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Fig. 3 Prevalence of mutant, mixed and wild type alleles in ANC, delivery and GP samples
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show contradicting results, with some showing no effect 
of IPTp-SP on the mutation prevalence [21, 30–32], while 
others do find higher prevalence in women reporting SP 
use [16, 33, 34]. These contradicting results could be due 
to a combination of different epidemiological settings 
and methodological approaches.
Evidence for a higher prevalence of dhfr mutations in 
low versus high transmission season had been observed 
in the general population in Burkina Faso by Geiger 
et  al. [15] and was therefore included in the analyses. 
However, in the current study an opposite seasonal 
effect of higher dhfr mutation prevalence in the high 
transmission season in delivery samples and no sea-
sonal effect for ANC samples was found. Increased 
dhfr mutations in the high transmission season have 
been described before in non-pregnant individuals in 
Indonesia, but the authors related this phenomenon 
to increased drug exposure, while this is not the case 
in the present study in which IPTp-SP was given year 
round [35]. Therefore, it seems that elevated transmis-
sion intensity increases the survival chances for mutant 
parasites, yet only at the end of pregnancy, since this 
phenomenon was not observed in ANC samples. The 
question is how this happens. Increased transmission 
likely increases the prevalence of mixed infections, 
which was indeed seen for delivery samples. This can 
result in within-host competition between malaria 
strains leading to suppression of one or both (or mul-
tiple) strains, as has been described before for P. falci-
parum in humans [16, 36] and Plasmodium chabaudi 
in mice [37]. Competition may result from limitations 
in available resources or can be immune mediated [38]. 
However, in the presence of drug exposure (like SP in 
delivery samples), a phenomenon called competitive 
facilitation could occur, in which drug-resistant P. fal-
ciparum suddenly have increased growth rates due to 
clearance of wild type strains after chemotherapy [16, 
37]. Thus the increased competition together with 
(recent) SP exposure could be an explanation for the 
selection of mutant parasites in delivery samples dur-
ing high transmission season.
Older age was significantly associated with decreased 
dhfr N51 and triple dhfr mutation prevalence in ANC 
samples and non-significantly in delivery samples. Asso-
ciations between age and dhfr mutation prevalence in 
pregnant women have not been frequently described in 
previous literature, but there were two reports that found 
no association [39, 40]. The same accounts for gravidity 
being positively associated with mutation prevalence in 
delivery samples. There has been one report that found 
a similar positive association [40], but in another study 
there was no effect of gravidity on mutation prevalence 
[39].
Strikingly, the resistance levels found in GP samples 
were comparable to samples collected at delivery and sig-
nificantly different (for all dhfr mutations and dhps S436 
mutations) from samples collected at ANC booking. SP 
exposure is unlikely to be the cause of the higher muta-
tion prevalence in GP samples; there was no seasonal 
malaria chemoprevention (SMC) programme with SP 
in the area and only infants at age two, three and four 
months received IPTi (thus excluded from the study). 
Only one person from the GP reported use of cotri-
moxazole (not included in analyses), a drug that shares 
the same drug targets of sulfadoxine and pyrimethamine 
[41]. Noteworthy however is the fact that the difference 
in resistance between GP and ANC samples was mainly 
found in mixed infections (considered mutants), whereas 
the difference between delivery and ANC samples was 
mainly found in pure mutants. The increase in mutation 
prevalence due to mixed infections in GP samples could 
not be explained by season of sampling as this was cor-
rected for in multivariate analyses. However, age distri-
bution was also a noticeable difference; GP participants 
were mostly children <15 years of age, whereas pregnant 
women were aged 15–45 years. In children, age has been 
shown to be inversely related to dhfr S108 and quintuple 
mutation prevalence [42, 43]. Nevertheless, the difference 
in prevalence of dhfr N51 and triple dhfr mutations com-
pared with ANC samples remained even if only GP par-
ticipants aged 15–45  years were included in the model. 
Therefore, other unknown factors that differ between 
pregnant and non-pregnant individuals must be involved 
in infection dynamics of wild type and mutant parasites.
The differences seen for dhps mutations between the 
three visits were less pronounced than for dhfr. Further-
more, almost no variables included in the multivariate 
models were significantly associated with mutation prev-
alence in the dhps gene. It is likely that selection of muta-
tions on the dhps gene is independent of selection of dhfr 
mutations and that it is driven by other factors [44].
There are some limitations to this study. First, samples 
from the general population were collected in a cross-
sectional survey at the end of the dry season. As dis-
cussed above, season had an effect on delivery samples, 
but did not seem to affect the differences found between 
ANC and GP samples. However, future evaluations of SP 
resistance mutations should consider performing year 
round surveys or repeated cross-sectional surveys in both 
low and high transmission season for the general popula-
tion. Additionally, it is possible that pregnant women and 
the GP are too diverse in infection dynamics and immu-
nity to compare these groups for mutation prevalence. It 
would therefore be interesting to evaluate SP mutation 
prevalence in P. falciparum samples from non-pregnant 
women of child-bearing age versus pregnant women.
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Another limitation is that there were quite some 
sequencing failures (5–22%), more so for delivery sam-
ples than GP and ANC samples. Failures were mainly due 
to low parasite density (median parasitaemia was 1 p/µl 
for failed dhfr and 2 p/µl for failed dhps sequences) and 
this was more common in delivery samples (Table  2). 
However, it is unlikely that these failures have led to a 
large bias in the resistance profiles. Parasitaemia was 
not associated with mutation prevalence in ANC sam-
ples and in delivery samples there was a trend of higher 
prevalence of mutations in samples with a low parasite 
density, so if the failed delivery samples would have been 
successfully sequenced they may even have increased the 
difference in mutation prevalence between early and late 
pregnancy. The GP samples showed an opposite trend of 
increased prevalence of mutations in samples with a low 
parasite density, but the difference in number of sequenc-
ing failures and parasitaemia with ANC samples was 
much smaller, thus the risk of bias is small.
Lastly, the current study lacks information on addi-
tional mutation sites in the dhfr and dhps genes, such 
as dhps A581, A613 and dhfr I164. In particular the 
dhps A581 mutation in combination with the quintu-
ple mutation, also known as the sextuple mutant, has 
been associated with reduced efficacy of IPTp-SP [45–
47]. Nevertheless, because the quintuple mutation was 
scarcely found in the study population, monitoring addi-
tional dhps mutations is important for the future but is 
unlikely to have impacted the current study results. Fur-
thermore, the dhps A581 and dhfr I164 mutation have 
not been previously found in Burkina Faso or its neigh-
bouring countries [14, 22].
Conclusion
This study shows that that resistance mutation profiles 
are dynamic and dependent on the study population 
(e.g., pregnant women in early and late pregnancy and 
also non-pregnant individuals) and transmission setting. 
Overall a high prevalence of dhfr N51, C59 and S108 and 
dhps S436 and A437 mutations is found in the study area. 
A combination of transmission intensity and SP exposure 
is a plausible cause of increased mutation prevalence in 
high transmission season in delivery samples. Never-
theless, it seems that selection of resistant mutants is a 
complicated process in which most likely aspects like 
epidemiology, immunity and infection dynamics and 
drug exposure are involved. These aspects are subject 
to change, as the adherence to the new WHO policy of 
offering IPTp-SP at each ANC visit is getting better and 
SMC with SP is being widely implemented, thus impact-
ing the selection and spread of SP resistance mutations. 
This fact and the new finding of quintuple mutants circu-
lating in the area therefore asks for thorough surveillance 
of emerging resistance against SP. Although currently 
IPTp-SP is still likely to remain effective in the study area, 
a search for alternative strategies is justified.
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